When the University of Rochester came knocking on the door of biopharmaceutical company Pharmaxis (ASX: PXS), it was a boost from a respected group of researchers for their lead drug candidate PXS-5505 which has continued to draw attention from around the world. By agreement with Pharmaxis, the University of Rochester embarked on preclinical work on
Read More
Breakthrough clinical trials into new treatments for bone marrow and liver cancer will soon commence after experienced institutional biotech investors with positive track records in companies such as Viralytics, Ophthea and Avita committed $7.2 million towards funding the trials for Pharmaxis (ASX: PXS) and their hero drug PXS-5505. Unlike other cancer treatment drugs on the
Read More
Our scars tell a story, whether it be grazed knees from the school yard or those mystery scrapes that make you wonder what on earth happened the night before. More often than not these minor scars give us funny stories, laughs and reminders not to touch hot irons. But for more serious injury following events
Read More